CXCL9, CXCL10, CXCL11, and CXCR3 in Dry Eye Syndrome
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00991679|
Recruitment Status : Completed
First Posted : October 8, 2009
Last Update Posted : October 8, 2009
The aim of this study is to investigate the expression of CXCL9, CXCL10, CXCL11, and CXCR3 in the tear film and ocular surface of patients with dry eye syndrome.
Thirty-three patients with dry eye (16 Sjögren's syndrome and 17 non-Sjögren's syndrome patients) and 15 control subjects were recruited. The concentrations of CXCL9, CXCL10, and CXCL11 in tears were measured using enzyme-linked immunosorbent assay. The correlation between chemokine levels and tear film and ocular surface parameters was analyzed. Expression of CXCL9, CXCL10, CXCL11, and CXCR3 in the conjunctiva was evaluated using immunohistochemistry. Flow cytometry was performed to count CXCR3+ cells and CXCR3+CD4+ cells in the conjunctiva.
|Condition or disease|
|Dry Eye Syndrome|
|Study Type :||Observational|
|Actual Enrollment :||48 participants|
|Observational Model:||Case Control|
|Official Title:||Expression of CXCL9, CXCL10, CXCL11, and CXCR3 in the Tear Film and Ocular Surface of Patients With Dry Eye Syndrome|
|Study Start Date :||February 2008|
|Actual Primary Completion Date :||October 2008|
|Actual Study Completion Date :||December 2008|
Normal control subjects
Normal control subjects who did not show the clinical symptom and findings of dry eye syndrome.
dry eye patients
Patients with dry eye syndrome who had symptoms of dry eye for more than 3 months, low tear film break up time (BUT, ≤7 sec), low Schirmer test (<10 mm), low tear clearance rate (<8X), and positive fluorescein or rose bengal vital staining (≥3) and were not treated with anti-inflammatory agents such as topical cyclosporine or steroids were included in the study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00991679
|Korea, Republic of|
|Chonnam National University Hospital|
|Gwangju, Chonnam, Korea, Republic of, 501-757|
|Study Director:||Kyung-Chul Yoon, MD, PhD||Department of Ophthalmology, Chonnam National University Medical School and Hospital, Gwangju, South Korea|